We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Rapid Lateral Flow Assay Measures Ovarian Cancer Biomarker CA125

By LabMedica International staff writers
Posted on 21 Sep 2020
Print article
Image: Upconverting nanoparticles: With the combination of NIR-excitation (980 nanometers) and detection at a lower wavelength, the autofluorescence from biological samples is totally eliminated, and the particles are detectable through tissue sections and even in whole blood (Photo courtesy of Kaivogen Oy)
Image: Upconverting nanoparticles: With the combination of NIR-excitation (980 nanometers) and detection at a lower wavelength, the autofluorescence from biological samples is totally eliminated, and the particles are detectable through tissue sections and even in whole blood (Photo courtesy of Kaivogen Oy)
A radically modified lateral flow immunoassay was able to detect the ovarian cancer biomarker glycosylated CA125 in serum samples and rapidly differentiate epithelial ovarian cancer from benign endometriosis and healthy controls.

Cancer antigen 125 (CA125) is a widely used biomarker for monitoring epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely limited. However, abnormal glycosylation of CA125 is a unique feature of ovarian cancer cells and detection of this biomarker could improve differential diagnosis of the disease.

In this regard, investigators at the University of Turku (Finland) sought to develop a quantitative lateral flow immunoassay (LFIA) to detect aberrantly glycosylated CA125, which would be superior to the conventional CA125 immunoassay for diagnosing EOC.

The inadequate clinical performance of traditional LFIAs has restricted the use of these assays for the detection of tumor biomarkers. Commonly, a LF strip consists of a nitrocellulose membrane, sample pad, conjugate pad, and absorbent pad, all laminated on a plastic backing card and placed in a plastic housing. Currently available LFIAs are either qualitative or semi-quantitative assays often with limited sensitivity. The detection method is usually based on visual interpretation of colloidal gold or colored nanoparticle reporters. Moreover, subjective visualization of test results has always been a major concern that could lead to false results.

Generally, fluorescent reporters provide superior sensitivity to colloidal gold and allow quantification of analytes. Among fluorescent reporters, crystalline lanthanide-doped parameterized particles (upconverting nanoparticles or Upcon nanoparticles) such as those produced by the biotech company Kaivogen Oy (Turku, Finland) are characterized by minimal auto-fluorescence background, resistance to photobleaching, and the ability to detect minute concentrations of biomarkers in biological samples. These unique features, which are based on the near-infrared excitation and anti-Stokes shifted luminescence, assure a successful implementation of Upcon nanoparticles in point-of-care diagnostics. The low-cost of infrared laser light source enabled the development of inexpensive portable readers, such as that produced by Labrox Oy (Turku, Finland).

In the current study, the investigators employed the Upcon nanoparticles quantitative LFIA for aberrantly glycosylated CA125 together with the Labrox Oy portable test reader. They found that with a 30 minute read-out time, the LFIA showed 72% sensitivity, at 98% specificity using diagnostically challenging samples with marginally elevated CA125 (35–200 U/milliliter), in comparison to 16% sensitivity with the classical CA125 LFIA.

"The received results are extremely promising for early cancer diagnostics. We are currently studying the functionality of similar approaches in other cancers. Detecting the disease as early as possible is extremely important when it comes to, for example, pancreatic cancer," said senior author Dr. Kim Pettersson, professor of biochemistry at the University of Turku.

The assay for glycosylated CA125 was described in the August 21, 2020, online edition of the journal Communications Biology.

Related Links:
University of Turku
Kaivogen Oy
Labrox Oy


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.